Patent · US Active

RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies

US9226976B2 · kind B2 · utility

32Cited by
10References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 20, 2012
Grant dateJan 5, 2016
Priority date
Expiry dateMay 2, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.